We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Venn Life Sciences Holdings Plc | LSE:VENN | London | Ordinary Share | GB00B9275X97 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 6.85 | 6.70 | 7.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMVENN
RNS Number : 6049J
Venn Life Sciences Holdings PLC
13 September 2016
Venn Life Sciences Holdings Plc
("Venn Life Sciences" or the "Company" or the "Group")
Appointment of Chairman
Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces the appointment of Allan Wood as Chairman to the Board with effect from 20 September 2016 taking over from Tony Richardson who has been acting as Executive Chairman since January 2016.
Allan Leigh Wood, aged 52, was previously Managing Director of Xansa Plc, an outsourcer of business processing solutions. Since then he has held a number of positions as a Non-Executive Director and Chairman of multiple companies across a broad range of fields where he has acquired skills that will benefit Venn.
Tony Richardson, Chief Executive Officer of Venn said: "I am delighted to welcome Allan to Venn. Allan has extensive relevant experience in scaling businesses in health services and related sectors and I believe will add significant value as we seek to continue our current growth trajectory. Allan's experience includes both organic business growth and M&A and together we can continue to build a successful and sustainable business for shareholders."
Mr. Wood has confirmed that there are no other items requiring disclosure in accordance with Schedule 2(g)(iii) to (viii) of the AIM Rules and the ESM Rules.
Current directorships Directorships or partnerships or partnerships in the last five years Oxehealth Limited Trustmarque Solutions Limited Ardvarna Investment Capital Healthcare Homes Holdings Limited Limited Eclipse Film Partnership HWH Plus Limited No. 22 LLP The Augusta Film Limited HWH Group Limited Liability Partnership WCI Group Trustee Company Limited Creare Franchise Limited Creare Communications (UK) Limited Creare Communications (Holdings) Limited Care UK (Urgent Care) Holdings Limited
Mr. Wood does not hold any ordinary shares in Venn Life Sciences.
Venn Life Sciences Holdings www.vennlifesciences.com Plc Tony Richardson, Chief Executive Tel: +353 154 99 341 Officer Davy (Nominated Adviser, ESM Adviser and Joint Broker) Fergal Meegan / Matthew de Vere Tel: +353 1 679 6363 White (Corporate Finance) Paul Burke (Corporate Broking) Hybridan LLP (Co-Broker) Claire Louise Noyce Tel: +44(0)20 3764 2341 Walbrook PR Ltd Tel: +44(0)20 7933 8787 or venn@walbrookpr.com Paul McManus Mob: +44(0) 7980 541 893
About Venn Life Sciences: Venn Life Sciences is a Contract Research Organisation providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK, Ireland and Europe wide representation - Venn specialises in rapid deployment and management of multisite projects. Venn also has an innovation division - Innovenn - focused primarily on breakthrough development opportunities in Skin Science.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOABUGDCUDBBGLD
(END) Dow Jones Newswires
September 13, 2016 02:01 ET (06:01 GMT)
1 Year Venn Life Sciences Chart |
1 Month Venn Life Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions